Clariant AG (CLRN) Q2 2026 Earnings Report

The call mixed positive operational and cash‑flow improvements (pricing, margin expansion in Q2, improved free cash flow conversion, increased cost savings and a favorable legal ruling) with clear and material headwinds concentrated in the Catalysts business and group‑level volume, currency and inflationary pressures. Management maintained guidance and outlined actions to offset disruption, but Middle East uncertainty, restructuring costs and higher leverage remain key risks.

Clariant reiterated FY2026 guidance that group sales in local currency should be around 2025 levels and EBITDA before exceptional items about 18%, while flagging continued volatility from the Middle East and expecting raw‑material inflation to moderate in Q4; this outlook relies on pricing and cost actions (Q2 pricing +3%) offsetting lower volumes (Q2 volumes -3.3%; Catalysts volumes -14.2%, ~2/3 of that due to Middle East delays). Relevant metrics and context: Q2 sales CHF 941m, H1 sales CHF 1.859bn; group EBITDA before exceptional items H1 CHF 331m (margin 17.8%), reported H1 EBITDA CHF 300m (margin 16.1%); free cash‑flow conversion LTM 52% (up 15pp); net debt increased by CHF 79.2m to a net‑debt/LTM‑EBITDA ratio of 2.2x (from 2.0x end‑2025). The company raised its performance‑improvement target by CHF 20m to a CHF 100m run‑rate by 2027 (expecting CHF 90m run‑rate by end‑2026), has achieved CHF 69m to date (CHF 10m in Q2), and booked CHF 24m of restructuring charges in Q2 with only mid‑single‑digit restructuring costs expected for the remainder of the year; business‑line assumptions: growth in Adsorbents & Additives, slight underlying growth in Care Chemicals, and lower Catalysts sales due to order delays.